1
|
Ganzon JG, Liaw CC, Lin YC, Lin ZH, Wang CH, Chen CY, Chuang KH, Kuo YH. New ent-kaurene and germacrene derivatives from Mesona procumbens Hemseley and their biological activity. Nat Prod Res 2022:1-9. [PMID: 35105219 DOI: 10.1080/14786419.2022.2034811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Mesona procumbens Hemseley is a well-known traditional herbal medicine used for heat-related ailments. In Taiwan, boiled extracts of M. procumbens are also used as desserts called grass jelly. In this study, the hexane extract from 75% EtOH of M. procumbens showed potent activities on inhibition of E. coli β-glucuronidase (eβG) and NO production and cytotoxicity against MCF-7 and HepG2 cancer cell lines. Furthermore, using various flash columns and HPLC chromatography on the bioactive layer led to the isolation of twelve compounds (1-12), including a new ent-kaurene, mesokaurol A (1), and a new germacrene derivative, mesogermapene A (2). Their structures were elucidated by extensive spectroscopic analyses, especially 2 D NMR and mass data. Biological assays showed that compound 9 (linolenic acid) had specific activity on inhibition of eβG (68.27%) at 100 µg/mL but was non-inhibitory to human β-glucuronidase. Compound 1 possessed significant cytotoxicity against MCF-7 (EC50 = 9.76 µM) and HepG2 (EC50 = 8.64 µM) cancer cell lines.
Collapse
Affiliation(s)
- Jerome G Ganzon
- Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Taipei, Taiwan
| | - Chia-Ching Liaw
- Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Taipei, Taiwan.,Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan
| | - Yu-Chi Lin
- Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Taipei, Taiwan
| | - Zhi-Hu Lin
- Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Taipei, Taiwan
| | - Chang-Hung Wang
- Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan
| | - Che-Yi Chen
- Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan
| | - Kuo-Hsiang Chuang
- Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.,Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
| | - Yao-Haur Kuo
- Division of Chinese Materia Medica Development, National Research Institute of Chinese Medicine, Taipei, Taiwan.,Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.,Department of Research and Development, Starsci Biotech Co. Ltd, Taoyuan, Taiwan
| |
Collapse
|